Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Intrexon pulls in $95.2mm through FOPO

Executive Summary

Life sciences company Intrexon Corp. (synthetic biology) netted $95.2mm in a follow-on offering of 3.75mm shares at $27. The company earlier this month licensed, along with partner Ziopharm Oncology, the University of Texas MD Anderson Cancer Center’s technologies relating to CAR T-cells, which it will use with its own DNA platforms to develop and commercialize nonviral adoptive cellular therapies for cancer.
Deal Industry
  • Diversified
  • In Vitro Diagnostics
  • Pharmaceuticals
  • Research, Analytical Equipment & Supplies
  • Biotechnology
    • Synthesis Technologies, Production Processes
    • Large Molecule
      • Antibodies
    • Drug Discovery Tools
      • Bioinformatics
      • Genomics-Proteomics
      • Molecular Diversity
Deal Status
  • Final
Deal Type
  • Financing
    • FOPO

Related Companies